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Theanabolic effects of parathyroid hormone (PTH) on
bone formation are impaired by concurrent use of
antiresorptive drugs. We found that the release of
active transforming growth factor (TGF)-b1 during
osteoclastic bone resorption is inhibited by alen-
dronate. We showed that mouse Sca-1-positive
(Sca-1+) bone marrow stromal cells are a skeletal
stem cell subset, which are recruited to bone remod-
eling sites by active TGF-b1 in response to bone
resorption. Alendronate inhibits the release of active
TGF-b1 and the recruitment of Sca-1+ skeletal stem
cells for the bone formation. The observation was
validated in a Tgfb1/ mouse model, in which the
anabolic effects of PTH on bone formation are dimin-
ished. The PTH-stimulated recruitment of injected
mouse Sca-1+ cells to the resorptive sites was
inhibited by alendronate. Thus, inhibition of active
TGF-b1 release by alendronate reduces the recruit-
ment of Sca-1+ skeletal stem cells and impairs the
anabolic action of PTH in bone.
INTRODUCTION
Current therapies for osteoporosis and the prevention of osteo-
porotic fractures include the inhibition of osteoclastic bone
resorption by antiresorptive drugs, such as alendronate and
risedronate (Liberman et al., 1995; Cranney et al., 2002a,
2002b), and the stimulation of osteoblastic bone formation by
parathyroid hormone (PTH) (Neer et al., 2001; Kurland et al.,
2000; Orwoll et al., 2003). Concurrent use of antiresorptive
agents and PTH was expected to be more effective because
this approach would be expected to reduce bone loss and to
stimulate new bone formation. In clinical trials of concurrent
PTH and alendronate, however, the anabolic effects of PTH
were impaired by the antiresorptive agent alendronate (Finkel-
stein et al., 2003, 2010; Black et al., 2003). This finding suggests
that osteoclastic bone resorption is necessary for PTH-induced
bone formation but the mechanisms underlying this effect areCelobscure. An improved understanding of the role that bone
resorption plays in PTH-induced anabolic bone formation would
provide amechanistic rationale for the development of strategies
that permit the effective use of both PTH and antiresorptive
drugs in the treatment of osteoporosis.
In the adult skeleton, bone is remodeled constantly via bone
resorption by osteoclasts and bone formation by osteoblasts
occurring throughout life (Bonnick, 2006; Iqbal, 2000; Raisz,
2005; Zaidi, 2007). Normally, these effects are balanced, but in
some situations, such as aging or certain pathological condi-
tions, bone resorption exceeds bone formation and there is net
bone loss (Teitelbaum, 2000; Riggs, 1991; Parfitt, 1982). In the
remodeling cycles, bone formation occurs at newly formed
resorptive sites and maintains the bone microarchitecture and
its mechanical properties (Hill, 1998). Bone marrow stroma is
composed primarily of nonhematopoietic stromal cells (BMSCs),
a subset of which is multipotent, able to differentiate into osteo-
blasts, chondrocytes, stromal cells that support hematopoiesis,
andmarrow adipocytes. The term ‘‘skeletal stem cells’’ has been
suggested for bone marrow-derived, multipotent, and self-re-
newing stromal cells capable of generating skeletal cell types
in vivo (Bianco et al., 2008). The bone formation is achieved by
murine Sca-1-positive (Sca-1+) BMSCs that are recruited to
the bone resorptive sites by the release of factor(s) during oste-
oclastic bone resorption, e.g., the active form of transforming
growth factor (TGF)-b1 (Tang et al., 2009). This TGF-b1-medi-
ated coupling process is essential for balancing bone resorption
and formation (Tang et al., 2009). In the current study, we inves-
tigated the role of the release of active TGF-b1 during osteo-
clastic bone resorption on the anabolic effects of PTH on bone
formation.RESULTS
The Effects of Combined Use of PTH and Alendronate
on Bone Formation Are Not Additive
To investigate the cellular mechanism responsible for the
impaired anabolic effects of PTH on bone formation during
combined therapy with antiresorptive drugs, we analyzed mice
at an age when the bone mass is in decline but active bone re-
modeling is still occurring (Figure S1 available online; Cao
et al., 2003; Beamer et al., 1996; Watanabe and Hishiya, 2005).l Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Inc. 571
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Figure 1. Effects of PTH Combined with
Alendronate on Trabecular Bone Formation
during Bone Remodeling in Mice
(A) Representative three-dimensional mCT images
of proximal tibiae from 8-month-old mice injected
with vehicle (Veh), PTH (1-34), alendronate (Aln),
and combination of PTH and alendronate
(PTH + Aln). Scale bar represents 1 mm.
(B–E) Quantitative mCT analysis of the secondary
spongiosa of proximal tibiae. Trabecular volu-
metric bonemineral density (TBMD) (B), trabecular
bone volume fraction (TBV/TV) (C), trabecular
thickness (Tb.Th) (D), and trabecular number
(Tb.N) (E) were measured (n = 10 for each treat-
ment group; *p < 0.05; n.s., not significant).
Data are presented as mean ± SEM. See also
Figure S1.
Cell Stem Cell
Stem Cell Recruitment during Bone RemodelingThe mice were injected with the vehicle, PTH, alendronate, or
pretreatment with alendronate followed by concurrent use of
PTH. The bone mass was estimated by microcomputed tomog-
raphy (mCT) analysis of the proximal tibia trabecular bone
(Figure 1A). Compared to treatment with the vehicle, treatment
with PTH or alendronate alone stimulated an increase in trabec-
ular bone mineral density (TBMD), but additive effects on TBMD
were not observed in mice treated with both drugs (Figure 1B).
The trabecular bone volume fraction (TBV/TV), thickness
(Tb.Th), and number (Tb.N) were higher in mice treated with
PTH or alendronate alone than those treated with the vehicle,
but again additive effects were not seen in the mice treated
with both drugs (Figures 1C–1E). These results suggest that
the combined administration offers no benefit over that achieved
by PTH alone.
PTH-Induced Recruitment of BMSCs to Bone
Remodeling Sites Is Inhibited by Alendronate
To investigate whether the PTH-induced osteogenic potential of
BMSCs is affected by the combined treatment with alendronate,
we isolated bone marrow cells from the mice treated as
described above, plated them at clonal density with irradiated
guinea pig marrow feeder cells to optimize the colony forming
efficiency, and counted the number of colony forming unit-fibro-
blasts (CFU-Fs). The isolated bone marrow cells were also
induced in osteogenic medium, and the number of colony form-
ing unit-osteoblast (CFU-Obs) was counted. Therewas no signif-
icant difference in the number of CFU-Fs in the bone marrow
cells isolated from the different treatment groups. The number
of CFU-Obs was higher in the mice treated with PTH alone
than that treated with the vehicle, and alendronate did not inhibit
the PTH-stimulated increase in the number of CFU-Obs (Figures
2A–2C), indicating that the PTH-induced osteoblast differentia-
tion potential of BMSCs was not affected by alendronate. We
then measured the effects of PTH and alendronate on the
number of osteoblasts and osteoclasts associated with trabec-
ular bone during remodeling. The number of osteoclasts was
significantly higher in PTH-treated mice than in mice treated
with the vehicle or alendronate. The number of osteoclasts in572 Cell Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Incmice treated with the combination was lower than that in mice
treated with PTH alone; the number was similar to that observed
when alendronate was used alone (Figures 2D and 2F). Similarly,
the number of osteoblasts in mice treated with PTH alone was
higher than that in mice treated with the vehicle, alendronate
alone, or both (Figures 2E and 2G). As a result, PTH-stimulated
bone formation rate and osteoid volume were inhibited by
alendronate (Figures 2H and 2I). These results suggest that the
alendronate-associated reduction in the number of osteoblasts
in the PTH-treated mice may result from an alendronate-associ-
ated interruption in the recruitment of BMSCs during bone re-
modeling because the PTH-induced osteoblast differentiation
potential of BMSCs was not affected by alendronate.
Alendronate Inhibits Release of Active TGF-b1 during
Osteoclastic Bone Resorption
We have shown that active TGF-b1 released during osteoclastic
bone resorption inducesmigration of BMSCs to the bone remod-
eling sites (Tang et al., 2009). We therefore examined whether
the inhibition of osteoclastic bone resorption by alendronate
affected the release of active TGF-b1. The levels of active
TGF-b1, as measured by enzyme-linked immunosorbent assay
(ELISA), were significantly higher in the bone marrow of mice
treated with PTH than in those treated with the vehicle or alendr-
onate alone (Figure 3A). The combined treatment resulted in
a reduction in the levels of active TGF-b1, but not in the levels
of total TGF-b1 (Figures 3A and 3B), suggesting that alendronate
inhibited activation of TGF-b1. The levels of active and total
TGF-b1 in the sera were similar in all the treatment groups
(Figures 3C and 3D). To confirm the observation, we measured
the levels of phosphorylated Smad2/3 (p-Smad2/3) in the bone
marrow cells because TGF-b1 induces phosphorylation of
Smad2/3 as its major signaling pathway (Macias-Silva et al.,
1996; Eppert et al., 1996; Lagna et al., 1996; Zhang et al.,
1996). We found that the PTH-induced enhancement of
p-Smad2/3 in the bone marrow cells was inhibited by combined
treatment with alendronate (Figures 3E and 3F). The levels of
p-Smad2/3 in the alendronate-treated bone marrow cells were
also lower relative than those in the vehicle-treatedmice (Figures.
BF IHG
D
E
TRAP
Goldner’s 
Trichrome
A
Veh AlnPTH PTH + Aln
BF
R
/B
S 
(m
m
3 /m
m
2 /y
)
O
V/
BV
 
(%
)
0
15
30
45
0
1
2
3
0
10
20
30
N.
O
c/
T.
Ar
 
(/m
m2
)
N.
O
b/
T.
Ar
 (/m
m
2 )
0
50
100
150
PTH+AlnVeh PTH Aln
CFU-F
CFU-Ob 0
20
40
60
0
10
20
30
40
CF
U-
F
n.s.
CF
U-
O
b
C
*
*
*
n.s. n.s.
*
* **
*
n.s.
* **
n.s.
**
*
*
*
n.s.
n.s.
Figure 2. Reduction of Osteoblast Number
in Trabecular Bone of Mice with Combined
Treatment of PTH(1-34) and Alendronate
(A) Colonies formed from harvested bone marrow
of the mice as indicated in CFU-F and CFU-Ob
assays (1 3 105 bone marrow nucleated cells
were plated into 6-well plates). The top panels
show 6-well plates containing CFU-Fs stained
with methanol green. The bottom panels show
6-well plates containing CFU-Obs stained with
Alizarin Red.
(B and C) The colony-forming efficiencywas deter-
mined by the number of colonies per 105 marrow
cells plated. Data are represented as mean ±
SEM of triplicate cultures of 0.1, 0.5, and 1 3 106
bone marrow nucleated cells from five individual
mice (*p < 0.05; n.s., not significant).
(D and E) Light micrographs of tartrate-resistant
acid phosphatase (TRAP) staining (D) and Gold-
ner’s Trichrome-staining (E) performed on trabec-
ular bone sections from distal femora of mice as
indicated. Black arrowheads indicate the osteoid
surface. Scale bars represent 50 mm.
(F–I) Bone histomorphometric analysis of trabec-
ular bone of the secondary spongiosa from the
mice as indicated. Number of osteoclasts per
tissue area (N.Oc/T,Ar) (F), number of osteoblasts
per tissue area (N.Ob/T.Ar) (G), bone formation
rate per bone surface (BFR/BS) (H), and osteoid
volume per bone volume (OV/BV) (I) were
measured (n = 10 for each treatment group;
*p < 0.05, **p < 0.01; n.s., not significant).
Data are presented as mean ± SEM.
Cell Stem Cell
Stem Cell Recruitment during Bone Remodeling3E and 3F). Histological analysis of mature osteoclasts and
p-Smad2/3-positive (p-Smad2/3+) cells in the femur trabecular
bone revealed a high number of p-Smad2/3+ cells in the micro-
environment of tartrate-resistant acid phosphatase (TRAP)-posi-
tive osteoclasts in mice treated with vehicle (Figure 3G),
indicating the release of active TGF-b1 during osteoclastic
bone resorption. The number of PTH-induced p-Smad2/3+ cells
was reduced significantly on combined use of alendronate, and
treatment with alendronate alone also resulted in a reduction in
the number of p-Smad2/3+ cells as compared to treatment
with vehicle (Figures 3G and 3H). The reduction in the number
of p-Smad2/3+ cells showed a positive correlation with the
reduction in the number of osteoclasts (Figures 3G and 3H).
Notably, the levels of active TGF-b1 and the number of
p-Smad2/3+ cells after the combined treatment were signifi-
cantly increased compared to treatment with alendronate alone,
most probably because of the stimulation of TGF-b1 expression
by PTH, but the increased p-Smad2/3+ cells were not in the
locale of osteoclastic resorption. Taken together, these results
indicate that alendronate inhibits the release of active TGF-b1
and does so through inhibition of osteoclastic bone resorption.
PTH-Induced Bone Formation during Bone Remodeling
Is Inhibited in Tgfb1–/– Mice
To investigate whether the alendronate-induced inhibition of
release of active TGF-b1 impairs the anabolic action of PTH in
bone, Tgfb1/ mice and their wild-type littermates (Tgfb1+/+)Celwere injected intermittently with PTH, alendronate, or the vehicle
for 4 weeks, and the anabolic effects of PTH on bone remodeling
were examined. As estimated by mCT analysis of the proximal
tibia trabecular bone, the three-dimensional bone parameters
(including TBMD, TBV/TV, Tb.Th, and Tb.N) were significantly
increased in the Tgfb1+/+ mice injected with PTH or alendronate
relative to the mice injected with the vehicle (Figures 4A–4E).
However, the effects of PTH on bone remodeling were dimin-
ished in the Tgfb1/ mice compared to their wild-type litter-
mates, whereas the effects of alendronate on bone formation
were not affected in the absence of TGF-b1 (Figure 4A). As
shown, PTH failed to increase TBMD and even reduced TBV/TV,
Tb.Th, and Tb.N in Tgfb1/ mice. In contrast, alendronate
increased TBMD, TBV/TV, Tb.Th, and Tb.N in Tgfb1/
mice in a fashion similar to that observed in Tgfb1+/+ mice (Fig-
ures 4B–4E). This reduction in the effects of PTH on bone in
Tgfb1/mice suggests that the release of active TGF-b1 during
bone resorption is essential for the effects of PTHon bone forma-
tion during remodeling.
Osteoblast Recruitment Is Uncoupled
from PTH-Induced Bone Resorption in Tgfb1–/– Mice
In Tgfb1/ mice, the levels of p-Smad2/3 in the remodeling
microenvironment were significantly lower than that in their
wild-type counterparts (Figure S2). On analysis of the osteoblast
differentiation potential of bone marrow cells isolated from the
Tgfb1/ mice, we found that the number of CFU-Fs andl Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Inc. 573
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Figure 3. PTH-Induced Release of Active
TGF-b1 during Bone Remodeling Is In-
hibited in Mice with Combined Use of
Alendronate
(A–D) The amount of active and total TGF-b1 in the
bone marrow (A, B) and serum (C, D) were
measured by ELISA (n = 5 for each treatment
group; *p < 0.05, **p < 0.01; n.s., not significant).
(E and F) Western blot analysis of the levels of
p-Smad2/3 and Smad2/3 in the bone marrow
cells. Fold changes of mean pixel of p-Smad2/3
to Smad2/3 were measured (n = 3 for each treat-
ment group; *p < 0.05).
(G) Images of distal femora sections from themice,
as indicated, were costained with TRAP (purple)
and p-Smad2/3 antibody (brown). b, bone. Scale
bar represents 100 mm.
(H) Counts of p-Smad2/3+ cells in total tissue area
and on osteoclast surface (N.p-Smad2/3+ cells/
T.Ar, Number of p-Smad2/3+ cells per tissue
area) (n = 10 for each treatment group;
*p < 0.05; n.s., not significant).
Data are presented as mean ± SEM.
Cell Stem Cell
Stem Cell Recruitment during Bone RemodelingCFU-Obs was similar in the bone marrow cells isolated from
Tgfb1/ mice and in those of their wild-type littermates; we
also found that PTH did not change the number of CFU-Fs but
increased the number of CFU-Obs, whereas alendronate had
no effect on either. Notably, the patterns of PTH or alendronate
effects on CFU-Fs and CFU-Obs in Tgfb1/ mice and their
wild-type littermates were comparable (Figures 5A–5C), indi-
cating that the effects of PTH and alendronate on CFU-Fs and
CFU-Obs are TGF-b1 independent. Further measurement of
the number of osteoblasts and osteoclasts during bone remod-
eling revealed that PTH stimulated both in Tgfb1+/+ mice
compared to mice injected with the vehicle or alendronate (Fig-
ures 5D–5G) but that PTH failed to stimulate osteoblasts in
Tgfb1/ mice when osteoclasts were stimulated (Figures 5E
and 5G), indicating uncoupled recruitment of BMSCs. As a result,
bone formation rate and osteoid volume were not stimulated by
PTH in Tgfb1/mice compared to the control mice (Figures 5H
and 5I). Thus, the recruitment of osteogenic BMSCs to the bone
remodeling sites was interrupted in the Tgfb1/mice, leading to
a reduction in the anabolic action of PTH on bone.
Sca-1+CD29+CD45–CD11b– BMSCs Are a Skeletal Stem
Cell Subset
Murine Sca-1+ BMSCs have been shown as bone marrow-
derived multipotent mesenchymal stem cells (Belema-Bedada
et al., 2008). We have shown that Sca-1+CD29+CD45CD11b
cells are recruited to bone remodeling sites in response to oste-574 Cell Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Inc.oclastic bone resorption. We therefore
examined the stem cell characteristics
of the Sca-1+CD29+CD45CD11b
BMSCs, which are more homogenous
cell population than Sca-1+ BMSCs.
Sca-1+ CD29+CD45CD11b BMSCs
were cultured in single cell suspensions
for single colony forming. Five individual,
well-separated colonies were selectedand the number of cells was individually expanded by passaging
(Figure 6A). To assess the multilineage differentiation capacity of
the five clonal strains, each clonal strain derived from a single
CFU-F underwent osteogenic, adipogenic, and chondrogenic
induction by different culture media (Figure 6B). All clones
were capable of osteogenesis, four of the five clones were
adipogenestic, and three clones were chondrogenetic,
indicating the multilineage differentiation capacity of Sca-
1+CD29+CD45CD11b BMSCs (Table S1).
The five green fluorescent protein (GFP)-positive (GFP+) clonal
strains were then injected individually into the femur cavity of 8-
week-old Rag2/mice with an immunodeficient background at
a density of 13 106 per injection (Figure 6C). GFP+ cells from the
injected bone were collected by fluorescence activated cell sort-
ing (FACS) 8 weeks after injection (Figure 6D), resulting in
2.03 104–63 104 cells, which were plated in culture at a density
of 1 3 103 cells per 100 mm dish. This procedure resulted in the
generation of at least two secondary CFU-Fs in each clonal strain
derived from five single CFU-Fs (Table S1). Importantly, all of the
colonies generated by the secondary CFU-Fs were positive for
Sca-1 and CD29 and negative for CD45 and CD11b
(Figure 6E). The five clonal strains were then pelleted, resus-
pended in matrigel, and injected underneath the renal capsule
of Rag2/ mice to generate heterotopic ossicles for assessing
their osteogenic differentiation capacity in vivo (Figure 6F).
Complete ossicles, including bone, sinusoids, and hematopoi-
etic components, were generated from individual clones
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Figure 4. Anabolic Effects of PTH on Bone Formation during Bone Remodeling Are Diminished in the Tgfb1–/– Mice
(A) Representative images of three-dimensional mCT of proximal tibiae from Tgfb1+/+ and Tgfb1/ mice treated with vehicle (Veh), PTH, or alendronate alone.
Scale bar represents 1 mm.
(B–E) Quantitative mCT analysis of the secondary spongiosa of proximal tibiae. TBMD (B), TBV/TV (C), Tb.Th (D), and Tb.N (E) were measured (n = 10 for each
treatment group; *p < 0.05, **p < 0.01; n.s., not significant). Data are presented as mean ± SEM.
Cell Stem Cell
Stem Cell Recruitment during Bone Remodeling(Figure 6G; Table S1). The lining cells on the bone surface and
osteocytes in the bone matrix were GFP+, indicating that the
donor cells induced osteogenesis (Figure 6G). These results
show that the Sca-1+CD29+CD45CD11b BMSCs are a skel-
etal stem cell subset.
Release of Active TGF-b1 Is Essential for Recruitment
of Sca-1+ Skeletal Stem Cells during PTH-Induced Bone
Remodeling
We then investigated whether the migration of Sca-
1+CD29+CD45CD11b cells to the bone remodeling sites is
interrupted in mice by the combined treatment of PTH and
alendronate. The GFP-labeled CFU-F-derived clonal strain was
injected into the femoral cavity of Tgfb1/ or Tgfb1+/+ mice
that had been treated with the vehicle, PTH, alendronate, or
the combination of PTH and alendronate. The injected cells
were detected by immunostaining the femoral sections with an
antibody specific for GFP 1 week after injection. In Tgfb1+/+
mice, the GFP+ cells were largely found at the bone remodeling
sites, as indicated by the presence of TRAP-positive osteo-
clasts, and PTH significantly enhanced the recruitment of the
donor cells to the bone resorption sites (Figures 7A and 7B). In
contrast, in Tgfb1/ mice and Tgfb1+/+ mice treated with
alendronate alone or in the combination of PTH and alendronate,
the GFP+ cells were dispersed largely in the bone marrow, with
a few at the bone surface (Figures 7A and 7B). The GFP+ cells
of Tgfb1/ or Tgfb1+/+ mice with different treatments were
also examined by flow cytometry analysis to assess their viability
in different bone marrow microenvironments. As shown in
Figures 7C and 7D, the survival rate of the GFP+ cells did not
differ significantly by treatment regimen. Together, these results
show that recruitment of Sca-1+ skeletal stem cells to the remod-
eling sites by TGF-b1 is essential for the anabolic effects of PTH
on bone formation during remodeling (Figures 7E).CelDISCUSSION
It is believed that bone resorption is essential for the anabolic
effects of PTH on bone formation. In human adults, PTH
enhances new bone formation through stimulation of bone re-
modeling; in each cycle of bone remodeling, new bone is formed
precisely at the sites that have recently undergone resorption.
The initial and critical step is to attract bone marrow multipotent
osteogenic cells to the resorption sites. The second step is to
promote the differentiation of the recruited cells into osteoblasts
that can secrete matrix proteins and minerals, thereby forming
new bone. We have identified that active TGF-b1 is released
during bone resorption and that it directs the migration of Sca-
1+CD29+CD45CD11b BMSCs as the primary factor to couple
bone resorption and formation (Tang et al., 2009). Therefore,
inhibition of TGF-b1 activation by alendronate causes insufficient
recruitment of the cells to the resorptive sites for the new bone
formation during PTH-stimulated bone remodeling, leading to
a reduction of bone remodeling, with no additive effects for the
concurrent use of PTH. Similarly, when osteoclast activity was
inhibited by osteoprotegrin (OPG), PTH anabolic action on
bone was also reduced in oophorectomized mice. In this case,
pretreatment with alendronate or OPG followed by either PTH
(1-34) alone or concurrent use of PTH(1-34) reduced osteoblasts
and serum levels of osteocalcin compared with PTH(1-34) treat-
ment alone (Samadfam et al., 2007). Moreover, the anabolic
action of PTH on bone is diminished in TGF-b1 knockout mice.
Thus, release of active TGF-b1 during osteoclastic bone resorp-
tion is essential for PTH-induced anabolic bone formation.
Bone formation is a complex process coupled with angiogen-
esis (Schipani et al., 2009; Street et al., 2002; Towler, 2007;
Wang et al., 2007), which involves the differentiation of many
types of cells. Therefore, recruitment of skeletal stem cells to
bone resorptive sites with potential differentiation into differentl Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Inc. 575
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6-well plates). The top panels show 6-well plates containing CFU-Fs stained with methanol green. The bottom panels show 6-well plates containing CFU-Obs
stained with Alizarin Red.
(B and C) The colony-forming efficiency was determined by number of colonies per 105 marrow cells plated. Data are represented as mean ± SEM of triplicate
cultures of 0.1, 0.5, and 1 3 106 bone marrow nucleated cells from five individual mice (*p < 0.05; n.s., not significant).
(D and E) Light micrographs of TRAP-staining (D) and Goldner’s Trichrome-staining (E) performed on trabecular bone sections of the secondary spongiosa from
distal femora of indicated treatment groups. Black arrowheads indicate osteoid surface. Scale bars represent 100 mm.
(F–I) Histomorphometric analysis of remodeling trabecular bone. N.Oc/T,Ar (F), N.Ob/T.Ar (G), BFR/BS (H), and OV/BV (I) were measured (n = 10 for each treat-
ment group; *p < 0.05, **p < 0.01; n.s., not significant).
Data are presented as mean ± SEM. See also Figure S2.
Cell Stem Cell
Stem Cell Recruitment during Bone Remodelingtypes of cells is critical for bone remodeling. Typically, the micro-
environment provides signals that direct the cell-lineage-specific
differentiation of the stem cells. The elasticity of the matrix plays
an important role, with a stiff matrix directing the differentiation of
bone marrow mesenchymal stem cells into osteoblasts (Engler
et al., 2006). At fresh resorptive sites, the bone mineral matrix
is exposed and lacks a covering of lining cells, providing a stiff
elastic microenvironment that is rich in bone matrix proteins for
the differentiation of skeletal stem cells to osteoblasts. Soluble
factors also contribute to the lineage specification of stem cells.
The osteotropic factors found in the bone matrix (including
BMPs, IGF-I, IGF-II, and PDGF) have been shown to induce
differentiation of skeletal stem cells into osteoblasts. These
factors are also released during osteoclastic bone resorption
as important components of the osteogenic microenvironment
at the resorptive sites. This mechanism warrants that new
bone formation always occurs at the freshly osteoclastic resorp-
tive sites to maintain the micro-architecture of the bone for its
mechanical property. Apparently, skeletal stem cells uncom-576 Cell Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Incmitted before being recruited to the osteogenic microenviron-
ment serve this purpose well.
Our recent study indicates that PTH induces endocytosis of
PTH1R and TbRII as a complex and that this feature coordinates
the signaling of both PTH and TGF-b in coupling bone formation
and resorption during the process of bone remodeling (Atfi and
Baron, 2010; Qiu et al., 2010). Interestingly, two clinical studies
indicate that sequential treatment of osteoporosis with PTH fol-
lowed by alendronate increase bone density more than does
PTH or alendronate alone (Rittmaster et al., 2000; Black et al.,
2005). Women who had received PTH(1-84) monotherapy for 1
year were randomly reassigned to an additional year with either
a placebo or alendronate. Alendronate treatment after PTH
therapy led to an increase of 31% in bone mineral density
compared with a 14% increase in the PTH-placebo group (Black
et al., 2005). Similar results were also obtained in another clinical
trial (Rittmaster et al., 2000). The benefit of sequential use of PTH
and alendronate is probably secondary to the fact that the
release of active TGF-b1 and the subsequent recruitment of.
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Figure 6. Characterization of Murine Sca-1+CD29+CD45–CD11b– BMSCs
(A) Five single CFU-F-derived cell strains were isolated and individually expended for characterization assays.
(B) In vitro differentiation of single CFU-F-derived cell strains into multilineage cells. (i) Murine BMSCs were cultured in osteogenic media for 4 weeks, and the
mineralized nodules were evaluated via Alizarin Red staining and visualized with light microcopy. (ii) Murine BMSCs were cultured in adipogenic media for
2 weeks, and the accumulation of numerous lipid vesicles within the cells was identified by Oil-red-O staining and visualized with light microscopy. (iii) Murine
BMSCs were cultured in chondrogenic media for 3 weeks, and the micromass pellet was stained with toluidine blue and visualized with light microscopy. The
inset shows a higher magnification of boxed area. Scale bars represent 100 mm.
(C) Illustration of bone marrow cavity transplantation of single CFU-F-derived cell strain.
(D) FACS analysis of the sorted GFP+ cells from the bone marrow cell suspension obtained from mice with single CFU-F transplantation.
(E) The sorted cells were replated to generate colonies. The expression levels of Sca-1, CD29, CD45, and CD11b of the secondary CFU-Fs were analyzed by
FACS analysis.
(F) Illustration of subrenal capsule transplantation of single CFU-F-derived cell strain.
(G) Formation of the heterotopic ossicle at 6 weeks after transplantation. (i, ii) Hematoxylin and eosin (H&E) staining of the heterotopic ossicle section (boxed area
in i corresponds to ii). (iii) Immune-staining of the heterotopic ossicle section with specific GFP antibody. GFP+ cells are shown on bone surface and in bone
matrix. b, bone; m, marrow. Black arrows indicate osteoblasts. Scale bars represent 50 mm.
See also Table S1.
Cell Stem Cell
Stem Cell Recruitment during Bone Remodelingskeletal stem cells during each cycle of PTH-stimulated bone re-
modeling are not impaired. Taken together, this mechanism
responsible for the alendronate-impaired anabolic effects of
PTH on bone suggests that the use of PTH before treatment
by an antiresorptive drug could be an effective therapy.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6J (wild-type) mice were purchased from Charles River and Tgfb1+/
were obtained from the MouseModels of Human Cancers Consortium Repos-
itory, US National Cancer Institute. Tgfb1+/– mice were crossed with Rag2/
mice to generate Tgfb1+/Rag2/mice to prevent the death of homozygotes
by autoimmune disease. Tgfb1+/–Rag2/mice were maintained as heterozy-
gotes and were crossed to generate Tgfb1/Rag2/ and Tgfb1+/+Rag2/
mice.
In the combined PTH and alendronate therapy model, 8-month-old C57BL/
6J male mice were subcutaneously administered alendronate (A4978, Sigma-
Aldrich) or a vehicle (equivalent volume of sterile phosphate buffer saline [PBS])
at a dose of 50 mg/kg three times weekly for 8 weeks. For the last 4 weeks, the
mice were subcutaneously injected PTH(1-34) (Bachem, Inc., 40 mg/kg/day) orCelvehicle (equivalent volume of 1 mM acetic acid in PBS) five times per week.
Sixty C57BL/6J mice were classified into four different groups, with 15 mice
per group: (1) Veh, the mice were injected with the vehicles of both PTH
(1-34) and alendronate; (2) PTH, the mice were injected with both PTH(1-34)
and vehicle of alendronate; (3) Aln, the mice were injected with both alendro-
nate and vehicle of PTH(1-34); and (4) PTH + Aln, the mice were injected with
both alendronate and PTH(1-34).
In themodel of Tgfb1/Rag2/mice injectedwith PTH and alendronate, 2-
month-old male Tgfb1/Rag2/ and Tgfb1+/+Rag2/ mice were injected
with PTH(1-34) (40 mg/kg/day, five times per week), alendronate (50 mg/kg
three times weekly), or vehicle as described above for 4 weeks (15 per group).
All animals were maintained in the Animal Facility of the Johns Hopkins
University School of Medicine. The experimental protocol was reviewed and
approved by the Institutional Animal Care and Use Committee of the Johns
Hopkins University, Baltimore, MD, USA.
Isolation and Culture of Murine BMSCs
Bone marrow cells were collected from 6-week-old wild-type male C57BL/6
mice euthanized by cervical dislocation; the cells were cultured with Minimum
Essential Medium [alpha] (a-MEM, Mediatech, Inc.) supplemented with peni-
cillin (100 U/ml, Sigma-Aldrich), streptomycin sulfate (100 mg/ml, Sigma-Al-
drich), and 20% lot-selected fetal bovine serum (FBS, Atlanta Biologicals) atl Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Inc. 577
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Figure 7. PTH-Induced Recruitment of Sca-1+ Skeletal Stem Cells to Bone Remodeling Sites Is Inhibited with Combined Use of Alendronate
or in Tgfb1–/– Mice
(A) Femur sections from the indicated mice transplanted with single CFU-F-derived GFP+Sca-1+CD29+CD45CD11b clonal strain were stained with TRAP and
the antibody to GFP. b, bone. Scale bar represents 25 mm.
(B) Number of GFP+ cells on bone surface 1 week after transplantation wasmeasured and presented as cells per millimeter of bone perimeter in sections (n = 5 for
each treatment group; *p < 0.05 versus Tgfb1+/+ treated with Veh, #p < 0.01 versus Tgfb1+/+ treated with PTH; n.s., not significant).
(C) GFP+ cells from bone marrows and compact bones 1 week after transplantation were assessed by flow cytometry analysis.
(D) Percentage of GFP+ cells is shown (n = 3 for each treatment group; n.s., not significant).
(E) Model of blunting anabolic effects of PTH on bone formation by alendronate. PTH enhances recruitment of Sca-1+ skeletal stem cells by stimulating bone
remodeling and releasing active TGF-b1 (left). Alendronate impairs PTH anabolic effects on bone formation by inhibiting the recruitment of Sca-1+ skeletal
stem cells (right).
Data are presented as mean ± SEM.
Cell Stem Cell
Stem Cell Recruitment during Bone Remodeling37C in a 5% CO2 humidified incubator. After 72 hr of adhesion, nonadherent
cells were removed and adherent cells were cultured an additional 7 days with
a single media change. The adherent cells were then retrieved by trypsin
digestion. Cells aliquots were incubated for 20 min at 4C with phycoerythrin
(PE)-, fluorescein isothiocyanate (FITC)-, peridinin chlorophyll protein (Per
CP)-, and allophycocyanin (APC)-conjugated antibodies against mouse Sca-
1, CD29, CD45, and CD11b (Bio-legend). Acquisition was performed on a fluo-
rescence-activated cell sorting (FACS) Aria model (BD Biosciences), and
analysis was performed with a FACS DIVE software version 6.1.3 (BD Biosci-
ences). The sorted CD29+Sca-1+CD45CD11b cells were enriched by further
culture. To isolate individual clonal strains, the sorted cells were passed
consecutively through 16- and 20-gauge needles to obtain single cell suspen-
sions. 13 103 cells were cultured in 100 mm dishes for single colony forming.
Individual, well-separated colonies were selected with cloning cylinders as578 Cell Stem Cell 7, 571–580, November 5, 2010 ª2010 Elsevier Increported (Kuznetsov et al., 1997; Sacchetti et al., 2007), and the number
of cells was individually expanded by passaging and confirmed by flow
cytometry.
In Vitro Differentiation Assays of BMSCs into Multilineage Cells
For osteogenic differentiation, cells were seeded at a density of 5 3 103/cm2
with a-MEM supplementedwith 10%FBS, 107M dexamethasone (Sigma-Al-
drich), 10 mM b-glycerol phosphate (Sigma-Aldrich), and 50 mM ascorbate-2-
phosphate (Sigma-Aldrich). Cultures in a-MEM supplemented with 10% FBS
served as a negative control. After 3 weeks of differentiation, themineralization
capacity of the cells was evaluated by Alizarin Red staining (2% of Alizarin Red
S [Sigma-Aldrich] dissolved in water with the pH adjusted to 4.2).
For adipogenic differentiation, cells were seeded at a density of 13 104/cm2
with a-MEM supplemented with 10% FBS, 106 M dexamethasone, 0.5 mM.
Cell Stem Cell
Stem Cell Recruitment during Bone RemodelingIBMX (Sigma-Aldrich), and 10 ng/ml of insulin (Sigma-Aldrich) for 2 weeks.
Cultures of cells in a-MEM supplemented with 10% FBS served as a negative
control. Lipid accumulation was identified by Oil-red-O staining (0.5 g of
Oil-red-O [Sigma-Aldrich] were dissolved in 100 ml of isopropanol [Sigma-Al-
drich] and diluted to 60% with distilled water).
For chondrogenic differentiation, cells (1 3 106) were seeded in polypro-
pylene tubes with high-glucose D-MEMsupplementedwith 107Mdexameth-
asone, 1% ITS (Sigma-Aldrich), 50 mM ascorbate-2-phosphate, 1 mM sodium
pyruvate (Sigma-Aldrich), 50 mg/ml of proline (Sigma-Aldrich), and 20 ng/ml of
TGF-b3 (R&D Systems). Culture cells in high-glucose D-MEM supplemented
with 10%FBS served as a negative control. After 3 weeks in culture, the pellets
were fixed in 10% buffered formalin for 48 hr and embedded in paraffin. Then
4 mm thick sections were processed for toluidine blue staining (1 g of toluidine
blue [Sigma-Aldrich] was dissolved in 100 ml of 70% alcohol and diluted to
10% with 1% sodium chloride, pH adjusted to 2.3).
CFU-F and CFU-Ob Assays
At the time of euthanasia, bone marrow from femoral, tibial, and humeral
medullary cavities were collected, and cell numbers were determined after
removal of red blood cells with Zapoglobin (Coulter Corp.). The numbers of
CFU-Fs and CFU-Obs in murine bone marrow isolates and in cultures of
bone marrow cells were determined in cocultures with irradiated guinea pig
marrow cells, as reported (Kuznetsov and Gehron, 1996). In brief, marrow cells
were obtained from the femurs and tibiae of 2-month-old female Hartley
guinea pigs by flushing with a 22-gauge needle and then were resuspended.
Cells were g-irradiated with a Co57 source for 50 min at 1.2 Gy/minute, as
reported (Di Gregorio et al., 2001). After rinsing by centrifugation, cells were
resuspended in a-MEM medium with 20% FBS, counted and cultured at
2.5 3 106 per well of a 6-well plate.
For assay of CFU-F and CFU-Ob number, 0.1, 0.5, or 1 3 106 murine
marrow cells were plated into 6-well plates in 3 ml of a-MEM supplemented
with glutamine (2 mM), penicillin (100 U/ml), streptomycin sulfate (100 mg/ml),
and 20% lot-selected FBS. Duplicate cultures were established. After 2 to
3 hr of adhesion, unattached cells were removed, and 2.5 3 106 irradiated
guinea pig feeder cells (provided by Dr. Brendan J. Canning) were added
to cultivation medium of adherent cultures just after washing. On day 14,
cultures were fixed and stained with 1 mg/ml of methanol green. The colo-
nies containing 50 or more cells were counted. For CFU-Ob assay, the cells
were cultured with osteogenic medium as described above for 21 days and
analyzed with Alizarin Red staining. The colony-forming efficiency was deter-
mined by counting the number of colonies per 105 marrow cells plated.
Secondary passage of CFU-F assay was performed as reported (Sacchetti
et al., 2007).
Subrenal Capsule Transplantation
We pelleted 2 3 103 cells, resuspended them in 2 ml of matrigel, and then in-
jected them underneath the renal capsule of 8-week-old Rag2/ mice with
an immunodeficient background to generate heterotopic ossicles for histolog-
ical study, as reported (Chan et al., 2009). The mice were euthanized 6 weeks
after transplantation, and the transplants were processed for staining.
Bone Marrow Cavity Transplantation
Age-matched Tgfb1/ or wild-type littermates with an immunodeficient back-
ground (Tgfb1/Rag2/ and Tgfb1+/+Rag2/ mice, male) were used as
recipients. The mice were classified into different treatment groups (five in
each group) as described above. GFP-labeled cells in 10 ml of a-MEM were
injected into the bonemarrow cavity of the left femora, as previously described
(Tang et al., 2009). Themice were euthanized 1 week after transplantation, and
the distal femora were processed for staining. In some cases, cells were
collected from bone marrows and compact bones by collagenase digestion
as reported (Zhu et al., 2010), and the total number of GFP-positive cells
was assessed by flow cytometry analysis.
Microcomputed Tomography Analysis
Trabecular bone in metaphyseal secondary spongiosa of tibiae were analyzed
by microcomputed tomography (mCT). Procedures are described in detail in
the Supplemental Experimental Procedures.CelHistochemistry, Immunohistochemistry, and Histomorphometric
Analysis
Standard protocols were followed. Procedures are described in detail in the
Supplemental Experimental Procedures.
Biochemical and Cellular Assays
Details about ELISA and western blot analysis are provided in the Supple-
mental Experimental Procedures.
Statistical Analysis
Analyses of significant differences were performed by means of an analysis of
variance. Each experiment was performed in at least three independent
cultures/animals per genotype, treatment, and condition, and data are pre-
sented as mean ± SEM. A probability value of less than 5% was considered
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at doi:10.
1016/j.stem.2010.09.012.
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